Health - New York Post Online Edition
NYP
New York Post
Autos
Jobs
Real Estate
Dating
Health

Breast Cancer Current Topics in Breast Cancer

Cancer Experts Say, "Stick to Tamoxifen Until We Know More"


Medically Reviewed On: May 20, 2002

By Erica Heilman

Postmenopausal women receiving tamoxifen treatment for early-stage breast cancer following surgery, should not switch to a new class of drugs. At least not yet...

This is the latest news from the American Society of Clinical Oncology, the nation's leading group of cancer specialists.

Tamoxifen has been the standard treatment in postmenopausal breast cancer patients for sixteen years. But a newer class of hormonal therapies, called aromatase inhibitors, has shown very promising preliminary results in a recent clinical study comparing their safety and efficacy to that of tamoxifen, in early-stage breast cancer patients following surgery.

Aromatase inhibitors are currently used as a first-line treatment for advanced-stage, metastatic breast cancer, and the results of their performance in early-stage breast cancer are exciting to oncologists and patients alike. But thought leaders say that there is not enough long-term clinical data yet to warrant a switch from tamoxifen in these patients.

Below, Dr. Maura Dickler of the Memorial Sloan-Kettering Cancer Center, offers a basic introduction to both tamoxifen and aromatase inhibitors, and discusses the latest research developments.

First, can you give us a general definition of hormonal therapies for breast cancer, and explain how they work?
The term hormonal therapy describes a number of different treatment approaches, but the underlying idea is to reduce the supply of estrogen to the tumor. We can accomplish this in a number of ways by using various hormonal manipulations. The SERMs, or selective estrogen receptor modulators, interfere with estrogen at the level of estrogen receptor binding, and tamoxifen is the best known drug in this class.

The aromatase inhibitors are another class of drugs that reduce blood levels of estrogen in postmenopausal women. These drugs inhibit the production of estrogen that takes place in the muscle and fat of women that continues after menopause. In premenopausal women, estrogen production happens mainly in the ovary, and reducing ovarian estrogen production in these women can serve as a treatment for breast cancer. This can be accomplished by either surgery or medication (e.g. the LHRH-agonists).

And why does estrogen play such a central role in breast cancer?
Well, about two thirds of breast tumors 'express', or make, the estrogen and/or the progesterone receptor. A tumor that's estrogen or progesterone receptor positive is considered 'hormone sensitive', and women who have these tumors have the option of hormonal therapy for both the treatment of early stage and metastatic cancer.

Page 1 of 2 Next Page >>

NYP

NEW YORK POST is a registered trademark of NYP Holdings, Inc. NYPOST.COM, NYPOSTONLINE.COM, and NEWYORKPOST.COM are trademarks of NYP Holdings, Inc.

Copyright 2007 NYP Holdings, Inc. All rights reserved.

Copyright 2007 NYP Holdings